Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein.

Yasunaga T, Ikeda S, Koga S, Nakata T, Yoshida T, Masuda N, Kohno S, Maemura K.

Int Heart J. 2014;55(2):160-4. Epub 2014 Mar 14.

2.

Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.

Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2009 Mar;4(3):535-41. doi: 10.2215/CJN.04330808. Epub 2009 Feb 11.

3.
4.

In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy.

Vitale C, Cerquetani E, Wajngarten M, Leonardo F, Silvestri A, Mercuro G, Fini M, Ramires JA, Rosano GM.

Ital Heart J. 2003 Sep;4(9):627-32.

PMID:
14635381
5.

Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA).

Weiner SD, Ahmed HN, Jin Z, Cushman M, Herrington DM, Nelson JC, Di Tullio MR, Homma S.

Heart. 2014 Jun;100(11):862-6. doi: 10.1136/heartjnl-2013-304893. Epub 2014 Apr 8.

PMID:
24714919
6.

Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability.

Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, Yamaguchi K, Koshiba K, Yagi S, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Akaike M, Sata M.

J Cardiol. 2011 Sep;58(2):151-7. doi: 10.1016/j.jjcc.2011.04.005. Epub 2011 Jun 14.

7.

Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus.

Yang HS, Woo JE, Lee SJ, Park SH, Woo JM.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):5989-97. doi: 10.1167/iovs.14-14864.

PMID:
25159210
8.

Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation.

Hudzik B, Danikiewicz A, Szkodzinski J, Polonski L, Zubelewicz-Szkodzinska B.

Eur Cytokine Netw. 2014 Jul-Sep;25(3):41-5. doi: 10.1684/ecn.2014.0354.

PMID:
25373851
9.

Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.

Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ.

Coron Artery Dis. 2009 Jun;20(4):267-73. doi: 10.1097/MCA.0b013e32832c459c.

PMID:
19440065
10.

Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia.

Hamad RR, Eriksson MJ, Berg E, Larsson A, Bremme K.

Acta Obstet Gynecol Scand. 2012 Jan;91(1):50-6. doi: 10.1111/j.1600-0412.2011.01238.x. Epub 2011 Aug 29.

PMID:
21751969
11.

Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes.

Lee SJ, Lee DW, Kim KS, Lee IK.

Diabetes Res Clin Pract. 2001 Dec;54 Suppl 2:S81-92.

PMID:
11733113
12.

Effects of lower extremity revascularization on the endothelial functions measured with noninvasive brachial artery flow-mediated dilatation.

Unal O, Karatepe O, Ugurlucan M, Koc B, Filizcan U, Aksoy M.

Ann Vasc Surg. 2011 Oct;25(7):969-74. doi: 10.1016/j.avsg.2011.02.013. Epub 2011 May 6.

PMID:
21530156
13.

Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction.

Sakr SA, Abbas TM, Amer MZ, Dawood EM, El-Shahat N, Abdel Aal IA, Ramadan MM.

Int Heart J. 2009 Jul;50(4):407-19.

14.

Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.

Iwata A, Miura S, Tanaka T, Ike A, Sugihara M, Nishikawa H, Kawamura A, Saku K.

Coron Artery Dis. 2012 Aug;23(5):315-21. doi: 10.1097/MCA.0b013e328352ffec.

PMID:
22617341
15.

Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein.

Zhou Y, Ni Z, Zhang J, Zhang W, Wu Q, Shen G, Wang Y, Qian J.

Vasc Med. 2013 Apr;18(2):85-91. doi: 10.1177/1358863X13483864.

PMID:
23609129
16.

Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease.

Kang SM, Chung N, Kim JY, Koo BK, Choi D, Jang Y, Cho SY.

Echocardiography. 2002 Nov;19(8):661-7.

PMID:
12487635
17.

Effect of exercise training on vascular endothelial function in patients with stable coronary artery disease: a randomized controlled trial.

Luk TH, Dai YL, Siu CW, Yiu KH, Chan HT, Lee SW, Li SW, Fong B, Wong WK, Tam S, Lau CP, Tse HF.

Eur J Prev Cardiol. 2012 Aug;19(4):830-9. doi: 10.1177/1741826711415679. Epub 2011 Jul 1.

PMID:
21724681
18.

The effect of enhanced external counterpulsation on C-reactive protein and flow-mediated dilation in porcine model of hypercholesterolaemia.

Liu Y, Xiong Y, Liu D, Luo C, Zhang Y, Wu G, Xie Q, Dong Y, Zheng Z.

Clin Physiol Funct Imaging. 2012 Jul;32(4):262-7. doi: 10.1111/j.1475-097X.2012.01120.x. Epub 2012 Jan 26.

PMID:
22681602
19.

Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.

Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ.

Clin J Am Soc Nephrol. 2011 Apr;6(4):785-92. doi: 10.2215/CJN.09231010. Epub 2011 Feb 17.

20.

Cardiac rehabilitation decreases plasma pentraxin 3 in patients with cardiovascular diseases.

Fukuda T, Kurano M, Iida H, Takano H, Tanaka T, Yamamoto Y, Ikeda K, Nagasaki M, Monzen K, Uno K, Kato M, Shiga T, Maemura K, Masuda N, Yamashita H, Hirata Y, Nagai R, Nakajima T.

Eur J Prev Cardiol. 2012 Dec;19(6):1393-400. doi: 10.1177/1741826711422990. Epub 2011 Sep 13.

PMID:
21914683
Items per page

Supplemental Content

Write to the Help Desk